TEE
STSA

Tibra Equities Europe’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Tibra Equities Europe’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-35,000
Closed -$247K – 226
2021
Q2 		$247K Buy
+35,000
New +$189K 0.08% 217

Other funds holding STSA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tibra Equities Europe's STSA Position: Q3 2021 in Review

Tibra Equities Europe sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q3 2021, closing a stake of 35,000 shares — an estimated $247K sold.

Tibra Equities Europe first reported a position in STSA in Q2 2021 and held it in 1 quarter. The position peaked at $247K in Q2 2021. 45 funds tracked by Wall St. Rank hold STSA as of Q3 2021.

  • Tibra Equities Europe reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 35,000 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q3 2021, an estimated $247K.
  • Tibra Equities Europe first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Tibra Equities Europe's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $247K in Q2 2021.
  • 45 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on Tibra Equities Europe's 13F filing for Q3 2021, filed 15 Nov 2021.